Chronic viral HBeAg-negative hepatitis B: Epidemiological, clinical and biochemical characteristics in an outpatient descriptive cohort in Burkina Faso

Abstract

Our study aimed to describe epidemiological and diagnostic features in an outpatient's cohort with chronic HBeAg-negative hepatitis B. Patients and methods: A cross-sectional descriptive study with a retrospective data collection was implemented from January 2004 to April 2016 in the hepato-gastroenterology department of the University Teaching Hospital Yalgado Ouédraogo (CHU-YO) in Burkina Faso. Results: Overall 325 HBeAg negative patients met the inclusion criteria. The sex ratio was 1.5 and the mean age 38.7 years. The most frequent circumstance of diagnosis was the health check-up (54.5%). The mean HBsAg concentration and viral load were 7861.6 IU/mL and 32 237.20 IU/mL, respectively. Low or moderate inflammatory activity was found in 44% and 24% of patients, respectively at the liver biopsy; 32% presented a portal fibrosis with some septa (F2). 43.9% and 41.6% had low (A1) or moderate (A2) inflammatory activity, respectively at the hepatic fibrosis blood test, while 59.1% and 20.4% had low (F1) or moderate (F2) fibrosis stage, respectively. Of the five biochemical and virological profiles among the untreated patients, the profile 1 represented 67.2% of the sample. Conclusion:The proportions of negative HBeAg in chronic hepatitis B patients are increasing in Burkina Faso. Most of the patients have a high viral load, a low to moderate inflammatory activity or fibrosis stage.

Genetic variation of TLR3 gene is associated with the outcome of hepatitis b infection in mauritanian patients: case control study

“…The patient group mainly consisted of older males with normal ALT and AFP levels. The majority of patients had HBeAg negative chronic infection (inactive carriers), which is commonly seen in patients with chronic HBV infection in African regions [ 33 , 34 ] and other parts of the world [ 35 ]. This HBV profile was generally associated with a positive prognosis and low severity of liver disease [ 36 ].…”

Evaluation of the Diagnostic Performances of the SD-Bioline®HBeAg Rapid Test Used Routinely for the Management of HBV-Infected Individuals in Burkina Faso

“…Thus, the use of HBeAg as a marker of viral replication could aggravate the burden of HBV in resource-limited countries, particularly in its use for the prevention of mother-to-child transmission of HBV. For instance, in Burkina Faso, HBeAg-negative patients should be closely monitored, as around 77% rapidly progress to cirrhosis and HCC [29]. In addition, the advent of the COVID-19 pandemic has enabled several urban and rural laboratories to be equipped with molecular biology platforms.…”

Review on Determinants of Hepatitis B Viral Antigens and Antibodies among HBV Positive Patients in Sub-Saharan Africa

“…It is a major public health problem in terms of its severity and progression toward chronicity, as well as the number of affected subjects and the variety of clinical forms. (Somé et al, 2021).…”